Athira Pharma's Reverse Stock Split Announcement
Athira Pharma, Inc., a clinical-stage biopharmaceutical company focused on innovative treatments for neurodegeneration, recently made headlines with its announcement of a 10-for-1 reverse stock split. This strategic move, supported by the company's stockholders, aims to adjust the market perception and performance of its shares.
Details of the Reverse Stock Split
The reverse stock split will take effect shortly and is expected to play a significant role in enhancing the company's stock price. Athira's shareholders previously approved this split during the company's Annual Meeting, granting the board the necessary authority to finalize the ratio and timing.
On the effective date, which is set for the evening of September 17, 2025, every ten shares of the current common stock will be consolidated into one. This significant reduction aligns the total number of authorized shares from 900 million down to 90 million, streamlining the capital structure. The par value of the stock will remain unchanged at $0.0001.
Reasons for the Reverse Stock Split
Athira's management envisions this reverse stock split will help the company meet the $1.00 minimum bid requirement necessary for continued listing on the Nasdaq Capital Market. A higher stock price can potentially enhance the marketability and liquidity of Athira's common stock, making it more attractive to a broader range of investors.
Impacts on Shareholders and Stockholders
For shareholders holding their shares in book-entry form, no action is required; they will automatically receive post-split shares without needing to do anything. Those with brokerage accounts will also see their holdings adjusted to reflect this change in line with their brokerage's processes.
Future Prospects for Athira Pharma
Athira Pharma is dedicated to advancing its pipeline of drug candidates aimed at modulating the neurotrophic HGF system, which has the potential to alter the trajectory of neurological diseases. The reverse stock split is a part of its broader strategy to position the company for future growth and success in the competitive biopharmaceutical landscape.
Staying Informed
Patients and investors interested in learning more about Athira's innovative approach to treating neurodegenerative disorders can visit their official website. The firm actively shares updates and insights on their developments and progress.
Frequently Asked Questions
What is the purpose of Athira Pharma's reverse stock split?
The reverse stock split aims to increase the stock price to meet Nasdaq listing requirements and enhance marketability.
How will the reverse stock split affect my shares?
Shareholders will have their shares adjusted automatically, receiving one new share for every ten old shares.
What remains the par value of the common stock post-split?
The par value of Athira’s common stock will remain unchanged at $0.0001.
Is any action required from shareholders?
No action is needed from registered shareholders; adjustments will be made automatically.
Where can I find more information about Athira Pharma?
More information can be found on Athira’s official website, where they provide updates and details about their developments.
